Abstract 177P
Background
Ramcirumab (RAM) plus paclitaxel (PTX) is the standard second-line chemotherapy for metastatic gastric cancer. The ABSOLUTE trial showed that weekly nanoparticle albumin-bound (nab)-PTX was non-inferior to weekly PTX in terms of overall survival (OS). [Objective] This study aimed to evaluate the efficacy and safety of nab-PTX plus RAM compared with PTX plus RAM in metastatic gastric cancer patients, retrospectively.
Methods
Patients who received RAM plus nab-PTX or PTX in our institution from August 2015 to December 2018 were included in this retrospective study. (PTX plus RAM patients were administered from August 2015 to April 2018, and nab-PTX plus RAM patients received the combination from May 2018 to December 2018). Response rate, progression-free survival (PFS), OS and safety were assessed.
Results
A total of 79 patients were included in this study (24 in the nab-PTX plus RAM group and 55 in the PTX plus RAM group). Among the 17 patients with measurable lesions in the nab-PTX plus RAM group, 6 achieved PR (an objective response rate of 35%). Among the 38 patients with measurable lesions in the PTX plus RAM group, 8 achieved PR (an objective response rate of 21%). There was no significant difference between the two groups (p = 0.26), but nab-PTX plus RAM tended to produce a higher response rate than PTX plus RAM. The PFS was 5.7 months in the nab-PTX plus RAM group and 5.1 months in the PTX plus RAM group (p = 0.12). OS was not reached in the nab-PTX plus RAM group and was 8.6 months in the PTX plus RAM group (p = 0.27). The improvement rate of ascites did not differ between the two groups (38.4% in the nab-PTX plus RAM group and 40% in the PTX plus RAM group). Neutropenia was the most common grade 3 or 4 hematological toxicity, and there was no difference between the two groups (58.3% in the nab-PTX plus RAM group and 58.2% in the PTX plus RAM group). The incidence of any grade 3 or 4 non-hematological toxicity were also not different between the two groups.
Conclusions
This study suggests that nab-PTX plus RAM had almost similar efficacy and safety compared with PTX plus RAM in patients with metastatic gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract